Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mesoblast Limited ( (AU:MSB) ) has provided an announcement.
Mesoblast has received U.S. FDA clearance to proceed directly to a registrational clinical trial of its cell therapy Ryoncil in children with Duchenne muscular dystrophy, a genetic muscle‑wasting disease affecting about 15,000 individuals in the U.S. The study will enroll 76 patients aged five to nine, comparing seven Ryoncil infusions over nine months with placebo, and will use time‑to‑stand at nine months as the primary endpoint alongside standard of care.
The trial builds on Ryoncil’s established pediatric safety profile in graft‑versus‑host disease and preclinical efficacy signals in DMD models, aiming to harness its anti‑inflammatory mechanism to preserve muscle function and slow disease progression. By partnering with advocacy group Parent Project Muscular Dystrophy to support patient identification and trial awareness, Mesoblast is strengthening its position in neuromuscular disorders and potentially broadening the commercial and clinical reach of its flagship cell therapy platform.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a biotech company specializing in allogeneic, off‑the‑shelf cellular medicines targeting severe and life‑threatening inflammatory conditions. Its lead product, Ryoncil, is the first FDA‑approved mesenchymal stromal cell therapy, used in pediatric steroid‑refractory acute graft‑versus‑host disease, and it is advancing a broader pipeline in inflammatory and cardiovascular indications across global markets.
The company leverages proprietary mesenchymal lineage cell technology, extensive intellectual property protection extending to at least 2044 in major markets, and industrial‑scale manufacturing to supply cryopreserved cell therapies. Mesoblast has commercial partnerships in Japan, Europe and China, operates in Australia, the U.S. and Singapore, and is dual‑listed on the ASX and Nasdaq.
Average Trading Volume: 4,173,671
Technical Sentiment Signal: Hold
Current Market Cap: A$2.75B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.